ACTB and diffuse large B-cell lymphoma: These results suggest that NBD peptide is effective in inhibiting canonical NF-κB activity in dogs with DLBCL at doses ranging from 0.5–2.0 mg/kg and that dogs whose tumors have high levels of NF-κB activity (as determined by high p-p65:β-actin) are most likely to respond [47].